Defendant
8 cases as defendant.
Company overview. Lupin Inc. is a U.S.-incorporated affiliate of Lupin Limited, the Mumbai-headquartered global pharmaceutical group founded in 1968. In corporate-disclosure filings it lists Nanomi B.V., a Netherlands-based Lupin unit, as its direct parent, with Lupin Limited as ultimate parent. Lupin Limited is publicly traded in India (NSE/BSE: LUPIN; Reuters LUPIN.BO). Group scale, per PitchBook/Morningstar (2026), is roughly US$3.3 billion trailing-twelve-month revenue, a market cap of about US$10.6 billion, and roughly 28,000 employees. Lupin Inc.'s own headcount and revenue are not separately published.
Products / services / operations. Lupin Inc. functions as a U.S. holding/intermediate entity within the group's vertically integrated U.S. generic-drug business, alongside sister company Lupin Pharmaceuticals, Inc. (the group's Delaware-chartered U.S. commercial arm, with U.S. headquarters in Naples, Florida, and manufacturing/R&D in Somerset, New Jersey). The Lupin group develops and markets generic and branded formulations, complex generics (including respiratory and nasal products), biosimilars, and active pharmaceutical ingredients across therapy areas such as cardiovascular, anti-diabetic, respiratory, CNS, and women's health, selling in over 100 markets.
Patent-litigation posture. Lupin Inc. is an operating-group entity defending against a brand-company suit, not an NPE: the case data show 0 plaintiff appearances and 1 defendant appearance. The sole tracked matter, Neurelis, Inc. v. Lupin Inc. (District of Delaware), is a Hatch-Waxman/ANDA suit under 35 U.S.C. § 271, a case type common in Delaware; the docket names Lupin Inc. with co-defendants Lupin Limited and Lupin Pharmaceuticals, Inc.
Notable context. Neurelis — maker of VALTOCO® (diazepam) nasal spray and affiliated with China Medical System Holdings — alleges that Lupin's ANDA No. 220394 for a generic diazepam nasal spray infringes patents including U.S. Patent No. 12,521,400, triggering a 30-month stay through late 2027. Related Lupin entities have answered and counterclaimed. Lupin Inc. has no plaintiff-side assertion activity in the tracked database.
Neurelis asserted U.S. Patent 12337061 and additional patent(s) against Lupin entities in the District of Delaware, relating to ANDA No. 220394 for diazepam nasal spray strengths 5, 7.5, and 10 mg/spray. The case is pending with a bench trial set for the week of 2027-03-01.
Neurelis, Inc.'s ANDA suit against Lupin entities. Aggregator pages list the '664 patent among the consolidated Neurelis ANDA family, but the individual docket has not been independently confirmed to assert it.
Jazz sued Lupin over Lupin's ANDA No. 215911 for generic Xywav; the complaint expressly lists the '426 patent among ten patents-in-suit. Lupin answered and counterclaimed; the case was consolidated with later Lupin suits and the Teva action, with no final merits judgment on the '426 patent found.
Jazz Pharmaceuticals Ireland Ltd. sued Lupin Inc. in the District of New Jersey. The docket is listed in the patent's Google Patents record and was active with activity into 2026.
Jazz Pharmaceuticals, Inc. et al. sued Lupin entities in D.N.J. involving the '106 patent. The case was closed and later settled June 12, 2018 per Hagens Berman complaint; docket noted termination Jan. 15, 2016 per L. Civ. R. 11.2 certification.
Named as a related consolidated ANDA action under lead case 1:24-cv-00562-MN. The narrative groups these dockets in the same patent family and as likely asserting the '414 patent, but provides no separate patent list for this docket.
The '306 patent was asserted against Lupin. The case settled on June 12, 2018, as described in antitrust complaints.
Lupin action consolidated into the Jazz v. Amneal consolidated litigation, 2:13-cv-00391.